Methylation & Proteomics-Based Detection of Bladder Cancer
- Abbreviated Name
- BLADDER-PRE-VAL
- Lead Investigator
- Cairns, Paul — Fox Chase Cancer Center
- Coordinating Investigator
- Feng, Ziding — Fred Hutchinson Cancer Center
- Involved Investigators
-
- Feng, Ziding — Fred Hutchinson Cancer Center
- Kibel, Adam — Brigham and Womens Hospital
- Wei, John — University of Michigan Recruiting
- Wagner, Andrew — Beth Israel Deaconess Medical Center
- Sidransky, David — Johns Hopkins University
- Leach, Robin J — University of Texas Health Science Center at San Antonio
- Srivastava, Sudhir — National Cancer Institute
- Czerniak, Bogdan — The University of Texas MD Anderson Cancer Center
- Schoenberg, Mark P. — Johns Hopkins University
- Cairns, Paul — Fox Chase Cancer Center
- Sanda, Martin — Emory University
Abstract
Study never Launched
Aims
This study will test the sensitivity of gene methylation in the presence of clinically evident, pathologically confirmed bladder cancer. This study will test the specificity of gene methylation in two groups of participants without bladder cancer - requiring cystoscopy for hematuria and for foreign body (urinary stones, stents, and catheters) or infection.
Analytic Method
Quantitative real time methylation specific PCR (qMSP) of urine sediment DNA using a panel of several methylated gene markers.
Outcome
Study never Launched
Publications
- No publications available at this time for this protocol.
Biomarkers
- No biomarkers available at this time for this protocol.
Data Collections
- No data collections available at this time for this protocol.
- Start Date
- Feb 1 2008
- Estimated Finish Date
- Feb 1 2009
- Finish Date
- May 1 2010
- Protocol ID
- 226
- Protocol Type
- Collaboration
- Fields of Research
-
- Hypermethylation
- Collaborative Group
- Prostate and Urologic Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of bladder
- Phased Status
- 1